Teleflex Incorporated (TFX) fair value analysis
S&P 500 · Updated 2026-10-19
TFX price how computed
Forward Fair Value verdict
UndervaluedTFX is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $126.11
- Sector
- Healthcare
- 12-month range
- $100.34–$142.05
- Market cap
- $5.51B
- From 52-week high
- -11.2%
- Shares outstanding
- 43.7M
- Rank in Healthcare by discount to fair value
- #102 of 108
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-09-11.
Teleflex Incorporated is a medical device company that manufactures and distributes products used in critical care, anesthesia, surgery, and other clinical applications. The company operates globally, serving healthcare providers and patients across North America, Europe, and international markets.
TFX currently ranks #102 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $5.51B
- P/E (trailing)
- 14x
- Revenue (TTM)
- $2.6B
- Net margin
- -39.6%
- EPS (TTM)
- $8.75
- Gross margin
- 58.2%
- Debt / equity
- 0.99
- Revenue growth (3-yr avg)
- -7.9%
- Shares outstanding
- 43.7M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 39 · neutral
- 50-day average
- $135.62
- 200-day average
- $123.67
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
What our data shows for TFX
- Our model validated 17 trailing price-to-earnings windows for TFX, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $100.34–$142.05.
- The 14-day relative strength index sits at a neutral 39.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TFX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TFX news
TickrTrends' derived news-sentiment signal for TFX is currently leaning positive, computed from recent coverage.
- Teleflex (TFX): Guidance Cut Meets A Bigger Buyback Push (insidermonkey.com, 2026-09-04)
TickrTrends take: Teleflex's reduction in forward guidance typically pressures valuations, yet the company's simultaneous expansion of its buyback program suggests management believes current price levels present an opportunity to return capital efficiently to shareholders. Given TickrTrends' undervalued assessment of the Healthcare sector company, investors focused on valuation metrics should monitor whether the guidance reduction reflects temporary headwinds or signals a more persistent challenge to earnings power. The interplay between reduced expectations and aggressive share repurchases will be critical in determining whether the undervalued designation holds as new financial results emerge.
What people are saying
Follow the TFX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for TFX showed a notable shift this week, with the DCF cross-check band moving from an overvalued assessment to no indicator reading. The stock maintains an undervalued valuation verdict within the Healthcare sector.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TFX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), TFX is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TFX's TickrTrends verdict?
TFX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TFX compare to other Healthcare stocks?
TFX ranks #102 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is TFX overbought or oversold?
TFX's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
TFX vs ABT · TFX vs AMPH · TFX vs BTSG · TFX vs CI · TFX vs DVA